Compare Adaptive Biotechnologies Corp (ADPT) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ConocoPhillips — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while ConocoPhillips trades at $111.01 (market cap $132.11B). The key difference: ConocoPhillips is far larger — about 39.7× Adaptive Biotechnologies Corp's market cap, and ConocoPhillips pays a 3.1% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | COP | |
|---|---|---|
Market Cap | $3.33B | $132.11B |
Sector | Health | Energy |
52-Week High | $22.37 | $133.80 |
52-Week Low | $10.24 | $85.66 |
Enterprise Value | $3.19B | $149.08B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ConocoPhillips (COP) trades at $108.44, up 3.54% today, with strong analyst support (74.5% buy ratings) and a $148.86 consensus price target suggesting significant upside. The company maintains solid fundamentals with a 12.58% net margin and 11.25% ROE, though revenue has declined from $78.5B in 2022 to $58.9B in 2025. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $102-103 levels.
COP presents a compelling value opportunity with attractive valuation multiples (P/E 17.56, EV/EBITDA 5.81) and consistent cash flow generation. However, investors face risks from volatile oil prices, declining revenue trends, and geopolitical uncertainties affecting energy markets. The upcoming Q2 earnings report on August 6 will be critical for confirming the bullish analyst outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
